Date: 2014-03-18
Type of information: Development agreement
Compound: RhuDex®
Company: Medigene (Germany) Falk Pharma (Garmny)
Therapeutic area: Liver diseases - Digestive diseases - Autoimmune diseases
Type agreement: licensing
development
commercialisation
Action mechanism: RhuDex® is a CD80 antagonist that blocks undesired T-cell activation and thus has an immunomodulating and anti-inflammatory effect.
Disease: primary biliary cirrhosis and other indications in hepatology and gastroenterology
Details: * On March 18, 2014, Medigene has signed an exclusive global licence agreement with the company Dr. Falk Pharma GmbH for the development and commercialization of its drug candidate RhuDex® for indications in hepatology and gastroenterology. Falk Pharma will assume responsibility and all costs relating to the clinical development and marketing of RhuDex® in these therapeutic areas. Medigene will receive an upfront payment and future milestone payments from Falk Pharma, plus double-digit RhuDex® royalties. Falk Pharma will initially concentrate on development in primary biliary cirrhosis (PBC). Medigene retains the rights for RhuDex® in the indication areas rheumatoid arthritis, psoriasis and other autoimmune diseases.
Financial terms:
Latest news:
